Skip to main content
Journal of Research in Medical Sciences : The Official Journal of Isfahan University of Medical Sciences logoLink to Journal of Research in Medical Sciences : The Official Journal of Isfahan University of Medical Sciences
letter
. 2021 Sep 30;26:79. doi: 10.4103/jrms.JRMS_244_20

Estimated CD4+ count: Appraisal on cases with COVID-19

Beuy Joob 1,, Viroj Wiwanitkit 2,3
PMCID: PMC8548893  PMID: 34759996

Dear Editor,

COVID-19 infection is an emerging novel coronavirus infection.[1] This new infection started in China in December 2019. Now (March 7, 2020), it already causes health problem in more than 50 countries in all continents except for Antarctica. Clinically, this new infection causes acute febrile illness and severe respiratory distress might occur.[2,3,4] Regarding basic laboratory investigation, decreased lymphocyte count is a hematological finding from complete blood count.[2,3,4] Nevertheless, there has never reported on its effect of specific lymphocyte subsets. Here, the authors reappraised on clinical data on published data to estimate the CD4 + count in COVID-19. Based on available data on 278 cases with COVID,[2,3,4] the authors performed a summative analysis on total lymphocyte count (TLC) and additional estimation of CD4 count based on the mathematical model technique.[5] The referred mathematical model is “CD4 + count = 0.24 × TLC − 5.97.”[5] Based on summative analysis, the mean TLC is equal to 840 cells/μL, therefore, the derived estimated CD4+ count is equal to 195.63 cells/μL). Therefore, the low CD4+ count is observed, and this reflects the nature of immunodeficiency in COVID-19 infection. Further studies on immunopathological due to the new infection are recommended.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

  • 1.Hsia W. Emerging new coronavirus infection in Wuhan, China: Situation in early 2020. Case Study Case Rep. 2020;10:8–9. [Google Scholar]
  • 2.Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–9. doi: 10.1001/jama.2020.1585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395:507–13. doi: 10.1016/S0140-6736(20)30211-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Srirangaraj S, Venkatesha D. Absolute lymphocyte count as a surrogate marker for CD4 counts after six months of HAART initiation in a resource-limited setting in India. Indian J Med Res. 2012;135:895–900. [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Research in Medical Sciences : The Official Journal of Isfahan University of Medical Sciences are provided here courtesy of Wolters Kluwer -- Medknow Publications

RESOURCES